Today: 6 May 2025
26 June 2024
1 min read

India’s Pharma to Hit Rs 5.5 Trillion

The report showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years….reports Asian Lite News

India’s Domestic Pharma Formulations (DomForm) market, which includes branded generic medicines, is expected to more than double and cross Rs 5.5 trillion in the next 10 years at a CAGR of 10 per cent, according to a new report.

The report, by investment banking firm Avendus Capital, showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years.

However, with a gradual transition from a primarily doctor-branded prescription model, more stringent quality compliance, and government policies and regulatory measures, the market is expected to make a significant growth.

“We are encouraged by the government of India’s Pharma Vision 2047, which is aimed at making medicines more equitable, accessible, and affordable while ensuring high quality and more sustainable manufacturing practices. We believe that the sector will more than double from today, comfortably crossing about Rs 5.5 trillion in value by 2034,” the report said.

The report also predicted shifts in channel volumes, with trade generics and the unbranded “Generic Generics”, including Jan Aushadhi centres and government hospital procurement, gaining more traction.

“We estimate that the DomForm market will continue growing at 9-10 per cent CAGR in the next 10 years. With the expansion of trade generics and Jan Aushadhi channels, we expect about 30 per cent volume contribution from these in 10 years,” the report said.

Although off-patent generics currently account for nearly 100 per cent of the market, because of local manufacturing and process innovations, the prices of medicines are significantly lower than the global average.

Currently, more than 3,000 companies and almost 10,000 manufacturing units exist, yet they come with significant variations in quality standards.

Substandard, spurious and counterfeit drugs account for a staggering 20 per cent of the market, as per official testing.

ALSO READ: India’s Capex Fuels Capital Goods Surge

Previous Story

India’s Wedding Market Now $130 Billion

Next Story

Afghanistan Reaches T20 WC Semis

Latest from Business

Six OMCs Pump ₹290 Cr into Startups

The Union Minister said the country continues to stand as the world’s third-largest startup ecosystem….reports Asian Lite News Six oil marketing companies (OMC) in India have invested Rs 290 crore from their

India Dominates Global Digital Banking List

Indian banks have observed the most notable gains in day-to-day banking (+9.8 pp) and expanding relationships (+3.4 pp)….reports Asian Lite News As many as 9 Indian banks have been recognised as ‘Digital
Go toTop

Don't Miss

A flood of fake e-commerce websites amid festive season

Several such fake e-commerce platforms are now operational as India

Indian Startups Raise $307.8 Million in Funding This Week

Seventeen early-stage startups raised about $166.8 million, like mPokket, Ema,